期刊文献+

治疗高血压药物的经济学评价 被引量:4

Evaluation of Drug Treatment of Hypertension from the Point of View of Economics
下载PDF
导出
摘要 重视高血压治疗中的经济学评价,对利用我国有限的卫生资源来遏制高血压对人民群众的危害有着重要的现实意义。药物经济学对于药物治疗的成本和治疗的结果给予同样的关注。因为治疗高血压的费用,不仅涉及药物价格,还包括患者的危险水平,降压疗效和对临床终点事件的影响,以及治疗的依从性和安全性。因此药物经济学更强调整体成本和价-效比。低危病人,若非药价低廉,治疗的价-效比不够理想。而在高危的患者,价-效比越小越经济而不是药费越便宜越好。 Evaluating drug treatment of hypeitension from the point of view of economics has important practical significance. It is important to make best use of our restricted health resources, whilst preventing harm to patients from hypertension. Pharmacoeconomic analysis seeks to take into account both the cost and the effect of drug treatment, because the cost of drug treatment involves not only drug prices, but also the risk level to patients, the effect of lowering blood pressure, the impact of clinical end points and the compliance with treatment and safety of treatment. Pharmacoeconomics places an emphasis on overall costs and cost-effectiveness. Drug treatment is not very cost-effective for low-risk patients, unless drug prices are low. However, for high-risk patients, the lower the cost-effective ratio is the more economic rather than the cheaper drug.
作者 陈鲁原
出处 《心血管病学进展》 CAS 2006年第5期550-554,共5页 Advances in Cardiovascular Diseases
关键词 高血压 药物 治疗 经济学 hypertension drug treatment economics
  • 相关文献

参考文献16

  • 1徐端正.药物经济学及其分析[J].中国新药与临床杂志,2000,19(2):139-142. 被引量:487
  • 2陈文.药物经济学概论[J].中国医药导刊,2000,2(3):45-47. 被引量:37
  • 3陈文,高继明,毕康宁,杨莉.国内药物经济学评价研究文献的系统评估[J].中国药房,2004,15(1):28-31. 被引量:41
  • 4Schneeweiss SA,Soumerai SB,Maclure M,et al.Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers[J].Clin Pharmacol Ther,2003,74:388-400.
  • 5刘皋林,陶霞.高血压治疗的药物经济学概述[J].中国药学杂志,2005,40(2):81-84. 被引量:6
  • 6Dahlof B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):A multicentre randomised controlled trial[J].Lancet,2005,366:895-906.
  • 7胡善联.敏感度分析[J].卫生经济研究,2000,17(1):36-38. 被引量:25
  • 8林曙光,陈鲁原.治疗高血压的药物经济学评价[J].中华心血管病杂志,2003,31(3):236-237. 被引量:40
  • 9Fischer MA,Avorn J.Economic implications of evidence-based prescribing for hypertension:Can better care cost less[J]? JAMA,2004,291:1850-1856.
  • 10Jnsson B,Hansson L,Stalhammar NO.Health economics in the Hypertension Optimal Treatment (HOT) study:Costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension[J].J Intern Med,2003,253:472-480.

二级参考文献57

  • 1宋秉鹏,丁玉峰.药物经济学概述[J].药物流行病学杂志,1996,5(3):179-183. 被引量:305
  • 2陈文 胡善联.药物经济学研究[A].见:王龙兴主编.卫生经济学的理论与实践[C].上海:上海交通大学出版社,1998.230~ 247.
  • 3陈文.成本效果分析[A].见:胡善联主编.卫生经济学[C].上海:复旦大学出版社,2003.315~ 335.
  • 4许世斌 俞顺章 陈洁.上海市 2所医院鼻咽癌病例诊断治疗的成本-效果分析[J].中国卫生经济,1993,12(5):38-38.
  • 5Degli EE, Berto P, Ruffo P, et al. The PANDORA project: result of the cost of illness analysi. J Hum Hypertents. 2001. 15:329-334.
  • 6Degli EE, Sturani A, Degli EL, et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther ,2001,39:251-258.
  • 7Johannesson M, Dahlof B, Lintholm LH, et al. The cost-effectiveness of treating hypertension in elderly people-an analysis of the Swedish TrialOld Patients with Hypertension (STOP Hypertension). J Intern Med ,1993,234 : 317-323.
  • 8Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, Pharm D. Am J Manag Care , 1999, 5( Suppl 7):S449-454.
  • 9Dunn EC, Small RE. Economic of antihypertensive therapy in the elderly. Drugs Anging ,2001, 18: 515-525.
  • 10Pearce KA, Furberg CD, Psaty BM, et al. Cost-mininization and the number need to treat in uncomplicated hypertension. Am J Hypertens,1998, 11:618-629.

共引文献618

同被引文献26

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部